ALECTOR INC (ALEC)
Health Care · Clinical-stage biotechnology / drug development · NASDAQ
An early-stage biotech company developing novel therapeutic candidates for neurodegenerative diseases through preclinical research and clinical trials.
What ALECTOR INC does
Alector is a preclinical and clinical-stage biotechnology company focused on the research and development of therapeutic product candidates, primarily through the advancement of research programs from preclinical stages into clinical development. The company is targeting specific disease indications and pursuing regulatory approvals, including orphan drug designations where applicable. Alector relies on third-party collaborators and manufacturers to conduct clinical trials and manufacture product candidates.
Themes: clinical-stage biotechnology, drug development, preclinical research, orphan drug designation, neurology / neurodegeneration
Fundamentals
- Price$2.36 as of 2026-08-21 close
- Market cap$264M as of 2026-08-21
- 1-year return+4.0% 2025-08-21 close $2.27 → 2026-08-21 close $2.36
- P/En/a negative earnings
- Net margin-680.8% as of 2026-08-24
- ROE-295.2% as of 2026-08-24
- Debt / equity0.94 as of 2026-08-24
- Revenue growth (YoY)-79.2% as of 2026-08-24
- Revenue CAGR (3y)-46.0% SEC XBRL
- Beta0.59 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ALEC compares in its sector
- net profit marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ALECTOR INC looks technically
ALECTOR INC (ALEC) is trading 26.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed below its 200-day average about 30 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 3 trading days ago. It is 30.6% below its highest point of the past year.
Trend
9
| Distance from the 200-day | it is trading 26.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +26.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $1.75 | $1.75 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $1.86 | $1.86 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 18 calendar days ago — the swings before that are what the structure reading is measured on | 18 sessions |
| Wave structure | its recent swings can be read as a completed three-part downward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes below 1.455. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave downward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 30 trading days ago — a "death cross", a bearish long-term signal | 30 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 26.6% above | +26.6% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with buyers in control | 32.2 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 66, neither overbought (above 70) nor oversold (below 30) | 65.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($1.46 to $2.52) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 84.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 19 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $3.40 | $3.40 |
|---|---|---|
| From the 52-week high | it is 30.6% below its 52-week high (its highest price of the past year) | -30.6% |
| Above the 52-week low | it is 116.5% above its 52-week low (its lowest price of the past year) | +116.5% |
| Below the 52-week high | it is 30.6% below its highest point of the past year | 30.6% |
| Since a 20-day breakout | it made a new 20-day high about 3 trading days ago | 3 sessions |
| Since a 55-day breakout | it made a new 55-day high about 3 trading days ago | 3 sessions |
| All-time high | its highest closing price on record is $43.32 (set on 2021-07-02) | $43.32 |
| Given back of the 52-week move | over the past year its closes ranged ($1.14 to $3.32), and it has recovered around half of its fall from last year’s high — 56% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $2.49 to $2.56. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 56.0% |
| From the all-time high | it is 94.6% below its all-time high | -94.5% |
| Nearest price level | it is trading 2.6% above a support level at $2.30 — a price it turned at three times since 2025-09-02, most recently on 2026-05-26. Since 2024-08-21 it has 11 such levels below the current price and 4 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -2.6% |
| All-time low | its lowest closing price on record is $0.87 (set on 2025-04-09) | $0.87 |
| Above the all-time low | it is 171.3% above its all-time low | +171.3% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 99% of the past ~6 months) | 99th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1995 between its high and its low — about 8.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1995 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $1.22 and $2.49 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $1.22 – $1.85 – $2.49 |
| Typical daily range (% of price) | its price moves about 8.5% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 8.4% |
| Stretch from the 200-day average | it is trading 2.5 daily ranges above its 200-day average price (26.6% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.62× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 4 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 4 sessions ago |
|---|---|---|
| Since a bearish engulfing | 6 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 6 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.9% |
|---|---|---|
| Gap filled | a 2.6% gap down opened on 2026-08-17 has been "filled" 4 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 4 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 50.9 percentage points (the stock gained 53.2% while the market gained 2.3%) | +50.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 3.7 percentage points (the stock gained 6.8% while the market gained 3.1%) | +3.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 7.5 percentage points (the stock gained 18.6% while the market gained 11.1%) | +7.5% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 16.5 percentage points (the stock gained 4.0% while the market gained 20.5%) | -16.5% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 16% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 12.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +16.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 17% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $2.02 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | +17.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 13% above the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $2.08 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | +13.3% |
Price levels it has turned at before
ALEC last closed at $2.36 on 2026-08-21. Since 2024-08-21 it has turned at 11 prices below its last close and 4 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.30 | Support | 2.6% below the last close | turned there three times · 2025-09-02 to 2026-05-26 |
| $2.15 | Support | 8.8% below the last close | turned there three times · 2025-01-06 to 2026-07-02 |
| $2.64 | Resistance | 12.0% above the last close | turned there twice · 2026-03-10 to 2026-04-01 |
| $2.00 | Support | 15.1% below the last close | turned there four times · 2024-12-05 to 2026-05-21 |
| $2.85 | Resistance | 20.8% above the last close | turned there twice · 2025-09-30 to 2025-10-14 |
| $4.19 | Resistance | 77.4% above the last close | turned there twice · 2024-10-02 to 2024-11-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part downward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes below $1.46.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent death cross (50-day crossed below 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.63 mean, 1=Strong Buy…5=Strong Sell) — 5 analysts
- Mean price target$3.10 range $1.00 – $6.00; median $2.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALEC
- Consensus EPS estimate-$0.2283 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure risk: ability to demonstrate safety and efficacy of product candidates in clinical trials is uncertain and actual results may differ materially from expectations","Regulatory approval risk: company must obtain and maintain regulatory approval of product candidates, with timing and likelihood of approvals uncertain","Manufacturing and third-party dependence: continued reliance on third parties to conduct clinical trials and manufacture product candidates for preclinical studies and clinical trials"]
What changed in the latest 10-Q
AI-assisted comparison of ALEC's 10-Q filed 2026-05-07 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- AL037/AL137 Program section added with details on paired anti-amyloid beta antibody with ABC platform for Alzheimer's disease (filed 2026-05-07)
- AL050 Program section added describing glucocerebrosidase enzyme replacement therapy for Parkinson's disease and Lewy body dementia (filed 2026-05-07)
- ABC-Enabled siRNA Platform section added describing AL064/AL164 tau siRNA program, ADP062-ABC alpha-synuclein siRNA, and ADP065-ABC NLRP3 siRNA (filed 2026-05-07)
- Statement that nivisnebart Phase 2 PROGRESS-AD trial was discontinued in April 2026 due to futility analysis (filed 2026-05-07)
- Statement that AbbVie collaboration was terminated in February 2025 (filed 2026-05-07)
- Removed:
- Description of company as 'clinical stage biotechnology company with a mission to make degenerative brain disorders history' removed (filed 2025-11-06)
- Latozinemab (AL001) clinical program section removed, including INFRONT-3 Phase 3 trial results announced October 21, 2025 (filed 2025-11-06)
- Original nivisnebart description stating it was 'currently in clinical development' and enrollment completed in April 2025 with trial completion expected in 2026 (filed 2025-11-06)
- Statement about planned independent interim analysis in first half of 2026 for nivisnebart removed (filed 2025-11-06)
- Details about nivisnebart Phase 1 study in 88 healthy volunteers removed (filed 2025-11-06)
- AL137 Program as separate standalone section removed and consolidated into AL037/AL137 Program (filed 2025-11-06)
- GSK Amendment funding details ($140.5 million cost-sharing) removed (filed 2025-11-06)
- Reworded:
- Overview: Changed from 'clinical stage biotechnology company' to 'biotechnology company developing therapies for neurodegenerative diseases' (filed 2026-05-07)
- Overview: Rewording of therapeutic objectives from 'remove toxic proteins, replace critical deficient proteins, and restore immune and nerve cells' to 'removing pathogenic proteins, replacing deficient proteins, and restoring normal cellular function' (filed 2026-05-07)
- ABC platform description: Changed from 'versatility, tunability, and differentiated binding' to 'versatility, translatability, and differentiated binding' (filed 2026-05-07)
- ABC platform description: Changed from 'tunable TfR binding affinities' to 'wide range of TfR binding affinities and binding kinetics' (filed 2026-05-07)
- Nivisnebart section: Changed from ongoing trial status to completed discontinuation statement (filed 2026-05-07)
- Portfolio reference: Changed from discussing 'robust portfolio of therapies' to 'advancing a portfolio of programs' (filed 2026-05-07)
- Notes:
- The newer filing text appears truncated at the end (cuts off mid-sentence), limiting ability to assess later sections
- Comparison based on available complete sections from both filings
Risk Factors
- Added:
- Added 'such as international conflict' to the description of geopolitical events in the forward-looking statements list (2026-05-07 filing)
- Removed:
- Removed 'and other regions' from the patient estimates bullet point; now reads only 'United States, the European Union' instead of 'United States, the European Union, and other regions' (2025-11-06 filing had the broader language)
- Reworded:
- Risk Factors section page number changed from 24 (2025-11-06) to 21 (2026-05-07)
- Item 2 page number changed from 78 (2025-11-06) to 75 (2026-05-07)
- Item 3 page number changed from 78 (2025-11-06) to 75 (2026-05-07)
- Item 4 page number changed from 78 (2025-11-06) to 75 (2026-05-07)
- Item 5 page number changed from 78 (2025-11-06) to 75 (2026-05-07)
- Item 6 page number changed from 78 (2025-11-06) to 75 (2026-05-07)
- Signatures page number changed from 80 (2025-11-06) to 76 (2026-05-07)
- Notes:
- The financial statements sections show different reporting periods (March 31, 2026 vs. September 30, 2025) and different comparison periods, making direct balance sheet comparison not relevant to Risk Factors section analysis
- Only the forward-looking statements and table of contents sections were compared as they represent the actual Risk Factors disclosure sections provided
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 4 sells ($228225) — 3 selling insiders
- Last 180 days0 buys · 5 sells ($233048) — 3 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALEC's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding ALEC as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 12,799,811
- Reported value $27,519,595
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ALEC had 5,644,306 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ALEC had 5.06% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.92 days to cover at the same settlement.
- Reported short interest (shares) 5,644,306
- Short interest (% of shares outstanding) 5.06%
- Prior settlement (shares) 5,664,933
- Reported change -0.36%
- Days to cover (reported) 12.92
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Biogen (BIIB)
- Eli Lilly (LLY)
- Roche (RHHBY)
- AbbVie (ABBV)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALEC vs…
ALECTOR INC is found in…
Frequently asked questions
What does ALECTOR INC (ALEC) do?
Alector is a preclinical and clinical-stage biotechnology company focused on the research and development of therapeutic product candidates, primarily through the advancement of research programs from preclinical stages into clinical development. The company is targeting specific disease indications and pursuing regulatory approvals, including orphan drug designations where applicable.
What sector is ALECTOR INC (ALEC) in?
ALECTOR INC (ALEC) is classified in the Health Care sector. Its industry is Clinical-stage biotechnology / drug development. It trades on NASDAQ.
Who are ALECTOR INC's (ALEC) competitors?
Notable peers of ALECTOR INC (ALEC) include Biogen, Eli Lilly, Roche and AbbVie. This peer set is informational only — not financial advice.
Is ALECTOR INC (ALEC) overbought or oversold right now?
ALECTOR INC (ALEC) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 66, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALEC come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.